The Myelodysplastic Syndromes Channel on VJHemOnc is an independent medical education platform, supported with funding from Geron (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2024 | The recent approval of imetelstat in LR-MDS based on results of the IMerge trial
Yazan Madanat, MD, UT Southwestern Medical Center, Dallas, TX, discusses the recent approval of imetelstat, a telomerase inhibitor, for patients with lower-risk myelodysplastic syndromes (LR-MDS). In the IMerge trial (NCT02598661), which led to its approval, imetelstat administration resulted in a 40% transfusion independence rate and an 18% one-year transfusion independence rate. Dr Madanat highlights that a proportion of patients achieved cytogenetic responses and exhibited decreased variant allele frequency, indicating that the agent may be disease-modifying in LR-MDS. This interview took place at the 29th Congress of the European Hematology Association (EHA) in Madrid, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Honoraria: Taiho oncology, Stemline therapeutics, Morphosys, Sierra Oncology, Novartis, OncLive, MD Education, Rigel Pharmaceuticals, Blueprint Medicines; Consultancy: GERON, Blueprint Medicines.
